DiaMedica Therapeutics Inc. (DMAC) intrinsic value & 10-year financials
DiaMedica Therapeutics Inc. (DMAC) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $7.57
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -499.8%
- Free cash flow (FY2025)
- -$29.1M
DMAC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$32.8M | — | -$29.1M | — | -87.6% |
| FY2024 | — | -$24.4M | — | -$22.1M | — | -63.0% |
| FY2023 | — | -$19.4M | — | -$18.8M | — | -57.2% |
| FY2022 | — | -$13.7M | — | -$11.6M | — | -41.9% |
| FY2021 | — | -$13.6M | — | -$12.3M | — | -47.1% |
| FY2020 | — | -$12.3M | — | -$9.2M | — | -112.8% |
| FY2019 | — | -$10.6M | — | -$9.1M | — | -569.4% |
| FY2018 | $500.0K | -$5.7M | — | -$5.7M | -1352.2% | -3073.2% |
| FY2017 | — | -$4.3M | — | -$3.9M | — | -446.1% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
DiaMedica Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
DiaMedica Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -50.1% ROIC.
DiaMedica Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
DiaMedica Therapeutics Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.